
Erlotinib, docetaxel, and gefitinib in sequential cohorts with relapsed non-small cell lung cancer
Keywords: واکنش; Docetaxel; Epidermal growth factor; Erlotinib; Gefitinib; Non-small cell lung cancer; Response; Survival